

**BIOCON GROUP**

**FACT SHEET**

**December - 2018**

**BIOCON LIMITED (CONSOLIDATED)**  
**BALANCE SHEET**

(Rs Cr)

	December 31, 2018	March 31, 2018
<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Property, plant and equipment	4,169	3,630
(b) Capital work-in-progress	939	779
(c) Goodwill	26	26
(d) Other intangible assets	108	43
(e) Intangible assets under development	599	524
(f) Investments in associates and a joint venture	54	64
(g) Financial assets	-	-
Investments	279	-
Derivative assets	88	111
Other financial assets	30	25
(h) Income tax asset, net	150	127
(i) Deferred tax asset, net	369	193
(j) Other non-current assets	387	319
	<b>7,198</b>	<b>5,841</b>
<b>Current assets</b>		
(a) Inventories	996	723
(b) Financial assets		
Investments	453	611
Trade receivables	1,324	1,064
Cash and cash equivalents	476	501
Other bank balances	519	822
Derivative assets	64	99
Other financial assets	451	192
(c) Other current assets	142	137
	<b>4,425</b>	<b>4,149</b>
<b>TOTAL</b>	<b>11,623</b>	<b>9,990</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity share capital	300	300
(b) Other equity	5,626	4,881
<b>Equity attributable to owners of the Company</b>	<b>5,926</b>	<b>5,181</b>
Non-controlling interests	555	468
	<b>6,481</b>	<b>5,649</b>
<b>Non-current liabilities</b>		
(a) Financial liabilities		
Borrowings	1,740	1,790
Derivative liability	81	18
Other financial liabilities	-	-
(b) Provisions	57	49
(c) Other non-current liabilities	669	342
	<b>2,547</b>	<b>2,199</b>
<b>Current liabilities</b>		
(a) Financial liabilities		
Borrowings	259	130
Trade payables	1,152	1,006
Derivative liability	22	6
Other financial liabilities	752	556
(b) Provisions	66	47
(c) Income tax liability, net	190	89
(d) Other current liabilities	154	308
	<b>2,595</b>	<b>2,142</b>
<b>TOTAL</b>	<b>11,623</b>	<b>9,990</b>

<b>BIOCON LIMITED (CONSOLIDATED)</b>			
<b>PROFIT &amp; LOSS STATEMENT</b>			(Rs. Crores)
Particulars	9M FY 2019	9M FY 2018	Variance
<b>INCOME</b>			
Small molecules	1,301	1,082	20%
Biologics	1,066	529	101%
Branded formulations	523	462	13%
Research services	1,292	1,014	27%
Inter-segment	(196)	(127)	54%
<b>Revenue from operations #</b>	<b>3,986</b>	<b>2,960</b>	<b>35%</b>
Other income	121	139	-13%
<b>TOTAL REVENUE</b>	<b>4,107</b>	<b>3,099</b>	<b>33%</b>
<b>EXPENDITURE</b>			
Material & Power costs	1,588	1,302	22%
Staff costs	769	612	26%
Research & Development expenses*	198	165	20%
Other expenses	445	285	56%
<b>Manufacturing, staff &amp; other expenses</b>	<b>3,000</b>	<b>2,364</b>	<b>27%</b>
<b>EBITDA</b>	<b>1,107</b>	<b>735</b>	<b>51%</b>
Interest & Finance charges	55	44	23%
Depreciation & Amortisation	328	290	13%
Share of profit in JV / Associate, net	(12)	(16)	-25%
<b>PBT BEFORE EXCEPTIONAL ITEM</b>	<b>736</b>	<b>417</b>	<b>76%</b>
Exceptional item, Net	195	-	-
<b>PBT</b>	<b>931</b>	<b>417</b>	<b>123%</b>
Taxes	153	117	32%
Taxes on exceptional item	18	-	-
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>760</b>	<b>300</b>	<b>153%</b>
Minority interest	68	58	16%
<b>NET PROFIT FOR THE PERIOD</b>	<b>692</b>	<b>242</b>	<b>186%</b>
<b>EPS Rs.</b>	<b>11.5</b>	<b>4.0</b>	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	18	21	
* Gross Research & Development expenses	314	283	

<b>BIOCON LIMITED (CONSOLIDATED)</b>			
<b>PROFIT &amp; LOSS STATEMENT</b>			(Rs. Crores)
Particulars	Q3 FY 19	Q3 FY 18	Variance
<b>INCOME</b>			
Small molecules	469	369	27%
Biologics	449	190	136%
Branded formulations	212	156	36%
Research services	467	388	20%
Inter-segment	(56)	(45)	26%
<b>Revenue from operations #</b>	<b>1,541</b>	<b>1,058</b>	<b>46%</b>
Other income	25	34	-24%
<b>TOTAL REVENUE</b>	<b>1,566</b>	<b>1,092</b>	<b>43%</b>
<b>EXPENDITURE</b>			
Material & Power costs	590	469	26%
Staff costs	269	215	26%
Research & Development expenses*	77	53	45%
Other expenses	224	99	126%
<b>Manufacturing, staff &amp; other expenses</b>	<b>1,160</b>	<b>836</b>	<b>39%</b>
<b>EBITDA</b>	<b>406</b>	<b>256</b>	<b>59%</b>
Interest & Finance charges	19	15	27%
Depreciation & Amortisation	117	97	20%
Share of profit in JV / Associate, net	(13)	(6)	102%
<b>PBT BEFORE EXCEPTIONAL ITEM</b>	<b>283</b>	<b>150</b>	<b>89%</b>
Exceptional item, Net	6	-	-
<b>PBT</b>	<b>289</b>	<b>150</b>	<b>93%</b>
Taxes	46	36	27%
Taxes on exceptional item	-	-	-
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>243</b>	<b>114</b>	<b>114%</b>
Minority interest	26	22	20%
<b>NET PROFIT FOR THE PERIOD</b>	<b>217</b>	<b>92</b>	<b>136%</b>
<b>EPS Rs.</b>	<b>3.6</b>	<b>1.5</b>	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	7	12	
* Gross Research & Development expenses	106	94	

<b>BIOCON LIMITED (CONSOLIDATED)</b>			
<b>PROFIT &amp; LOSS STATEMENT</b>			(Rs. Crores)
Particulars	Q3 FY 19	Q2 FY 19	Variance
<b>INCOME</b>			
Small molecules	469	432	9%
Biologics	449	367	22%
Branded formulations	212	164	29%
Research services	467	419	12%
Inter-segment	(56)	(61)	-8%
<b>Revenue from operations #</b>	<b>1,541</b>	<b>1,321</b>	<b>17%</b>
Other income	25	54	-53%
<b>TOTAL REVENUE</b>	<b>1,566</b>	<b>1,375</b>	<b>14%</b>
<b>EXPENDITURE</b>			
Material & Power costs	590	506	17%
Staff costs	269	263	2%
Research & Development expenses*	77	77	0%
Other expenses	224	135	66%
<b>Manufacturing, staff &amp; other expenses</b>	<b>1,160</b>	<b>981</b>	<b>18%</b>
<b>EBITDA</b>	<b>406</b>	<b>394</b>	<b>3%</b>
Interest & Finance charges	19	19	-1%
Depreciation & Amortisation	117	112	4%
Share of profit in JV / Associate, net	(13)	1	-1489%
<b>PBT BEFORE EXCEPTIONAL ITEM</b>	<b>283</b>	<b>262</b>	<b>8%</b>
Exceptional item, Net	6	189	-
<b>PBT</b>	<b>289</b>	<b>451</b>	<b>-36%</b>
Taxes	46	55	-17%
Taxes on exceptional item	-	18	-98%
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>243</b>	<b>378</b>	<b>-36%</b>
Minority interest	26	23	13%
<b>NET PROFIT FOR THE PERIOD</b>	<b>217</b>	<b>355</b>	<b>-39%</b>
<b>EPS Rs.</b>	<b>3.6</b>	<b>5.9</b>	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	7	5	
* Gross Research & Development expenses	106	120	